FCF Yield

Biogen's FCF Yield of 6.8% means that for every $100 of its stock market value, the company generates $6.80 in free cash flow—cash left after operating and capital expenses—providing a measure of how much cash return an investor gets relative to the share price.

This yield sits well above the healthcare sector median of 3.3%, placing Biogen in the 91st percentile among its peers, indicating stronger cash generation versus most companies in its industry. The trend for this metric is not available, as both the year-over-year change and quarter-over-quarter change are marked N/A, and no historical values beyond the current 6.8% are provided. The combination of a high FCF Yield relative to peers with no trend data means there is a clear cash-flow opportunity at the current price, but the lack of directional movement makes it impossible to assess momentum or sustainability. This metric contradicts the overall NEUTRAL verdict, as a 6.8% yield in the top decile of the sector typically signals an attractive valuation that would lean toward a more positive assessment.

Frequently Asked Questions

Closest Sector Peers